Intersect ENT Stock News

Sientra (SIEN) delivered earnings and revenue surprises of -11.54% and 5.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.

Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.

DexCom (DXCM) delivered earnings and revenue surprises of -36% and 1.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SeaSpine (SPNE) delivered earnings and revenue surprises of -44.44% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 17.24% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT), which agreed to purchase Intersect ENT (XENT) for $1.1B in August, is said to be finalizing plans on potential divestitures in an effort to resolve U.S

Analysts expect that Intersect ENT, Inc. (NASDAQ:XENT) will post sales of $37.13 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Intersect ENTs earnings, with estimates ranging from $36.53 million to $37.82 million. Intersect ENT reported sales of $28.23 million in the same quarter last year, which would []

Parametric Portfolio Associates LLC lowered its stake in shares of Intersect ENT, Inc. (NASDAQ:XENT) by 8.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 32,861 shares of the medical equipment providers stock after selling 3,012 shares during the quarter. Parametric Portfolio Associates LLCs holdings []

Equities analysts expect Intersect ENT, Inc. (NASDAQ:XENT) to report earnings per share (EPS) of ($0.35) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Intersect ENTs earnings, with the lowest EPS estimate coming in at ($0.42) and the highest estimate coming in at ($0.30). Intersect ENT reported earnings per share of []

Lumature Wealth Partners LLC bought a new stake in shares of Intersect ENT, Inc. (NASDAQ:XENT) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,904 shares of the medical equipment providers stock, valued at approximately $106,000. Several other institutional investors have also bought []

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?